Background: Existing guidelines on screening children less than 5 years of age for developmental delay vary. In this systematic review, we synthesized the literature on the effectiveness and harms of screening for developmental delay in asymptomatic children aged 1-4 years.
T he preschool period of child development (age < 5 yr) is widely recognized as a uniquely sensitive period for the foundation of cognitive ability and related functioning. Intensive change typically occurs during this time across the domains of language, social and motor development. Intellectual disability and other developmental disabilities that often co-occur (e.g., autism spectrum disorders) frequently entail lifelong challenges with respect to daily functioning and well-being for individuals and caregivers, and are considered to be detectable during the preschool period. Many caregivers, researchers and policy-makers therefore argue that detection and intervention before the age of 5 years is essential to optimize outcomes for children and families. [1] [2] [3] Screening children at risk of intellectual disability and related impairment is an important challenge for health care providers and policy-makers. Global developmental delay has been defined in the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-V) as "the failure of an individual under age 5 to meet expected developmental milestones across multiple areas of intellectual functioning." 4 Developmental delay may be understood as the failure to meet expected milestones across a given domain of development (e.g., cognitive, language, social or motor development). The DSM-V emphasizes the difficulty in reliably assessing intellectual and related functioning among very young children during a period of intensive and variable developmental change. 4 
Screening for developmental delay among children aged 1-4 years: a systematic review
Within pediatric health care, policy decisions that address early detection and intervention for developmental delay involve a particularly complex balance of considerations. Parents of children with developmental disorders often report a sense of urgency to intervene as quickly as possible during essential developmental windows. There is also an important tension between intervening as early as possible and not overidentifying many children as developmentally delayed (i.e., too many false-positive findings). False-positive screen results for developmental delay can lead to unnecessary stigma, caregiver anxiety and excess cost, whereas false-negative results can lead to delays in treatment.
Existing guidelines and recommendations for screening children for developmental delay vary. In 1994, the Canadian Task Force on the Periodic Health Examination (now the Canadian Task Force on Preventive Health Care) found fair evidence to assess developmental milestones at each well-baby visit. 5 In another guideline in the same year, 6 the task force found good evidence to recommend against the use of the Denver Developmental Screening Test 7 in asymptomatic preschool children, as well as insufficient evidence for other screening tools. In 2015, the US Preventive Services Task Force assessed screening for speech and language delay in preschool children and found insufficient evidence for the use of screening instruments in children up to 5 years of age to detect speech and language delay in primary care. 8 Conversely, the American Academy of Pediatrics recommends screening for developmental delay using a standardized tool at 9, 18 and 24 or 30 months of age, 9 and screening for autism at 18 months and 24 months. 10 In Canada, Ontario has implemented an enhanced 18-month well-baby visit, which includes using the Nipissing District Developmental Screen (NDDS) as a surveillance tool to assess for global developmental delay. 11, 12 More than 20 years have passed since the last Canadian Task Force on Preventive Health Care guideline on developmental screening, necessitating a new review of the empirical literature to determine the current state of the evidence. The systematic review on which this article is based provided evidence for the task force to inform new recommendations on screening for developmental delay in children aged 1-4 years. This systematic review synthesizes the effectiveness and harms of screening for developmental delay in children with respect to improving cognitive, academic and functional outcomes.
Methods
We conducted a systematic review to address the effectiveness of screening for developmental delay in children aged 1-4 years who are not at risk or suspected of having developmental delay. This search was part of a larger, staged systematic review that investigated treatment of developmental delay and test properties of screening tests (details about the full review protocol are available at www.crd.york.ac.uk/PROSPERO; registration no. CRD42014009809). Results from the full review will be available on the Canadian Task Force on Preventive Health Care website (http://canadiantaskforce.ca/). Similar methods have been used by and are reported in other publications authored by our review team. [13] [14] [15] 
Key questions
This systematic review aims to answer the following questions: What is the effectiveness of screening children aged 1-4 years without suspected developmental delay to improve their outcomes? What is the optimal interval for screening for developmental delay? What is the incidence of harms of screening children aged 1-4 years without suspected developmental delay?
Search strategy
We searched MEDLINE, Embase and PsychINFO with no beginning date limitations through to June 16, 2015 . The published results of studies had to be available in either English or French. The effectiveness of the screening search was peer-reviewed using the PRESS format. 16 
Eligibility criteria
Details about the inclusion and exclusion criteria are shown in Table 1 . Because developmental delay poses a high burden at individual, family and societal levels, rigorous methodologic standards are essential to assess whether developmental screening tools are effective in meaningful ways. For this reason, we included only controlled cohort studies and randomized controlled trials (RCTs) to answer the question of benefits.
Study selection, quality assessment and data abstraction
Six team members, working in pairs, reviewed titles and abstracts of papers in duplicate; articles marked for inclusion by either member went on to full-text screening, which was performed independently by the same 6 team members. Disagreements were resolved through discussion and consensus.
One team member completed full data abstraction using a Web-based systematic review software program (DistillerSR, Evidence Partners), and a second team member verified this extraction; disagreements were resolved through discussion or by a third team member. All studies included to answer the question about effectiveness of screening were assessed by one team member using the Cochrane risk-of-bias tool 18 and verified by another team member. The quality of the evidence was determined based on the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methods (www.gradeworkinggroup.org) using GRADEPro software (version 3.2 for Windows, available at http://ims.cochrane. org/revman/other-resources/gradepro/download).
Statistical analysis
We could not perform a meta-analysis because of the paucity of studies. The effect estimates from the studies were reported in the form of relative risk (RR) for binary outcomes of interest such as referral rate and academic performance, and rate ratio for time to event outcomes such as time to referral. For studies that showed a significant effect for the effectiveness of screening for developmental delay, we added the estimates of absolute risk reduction, absolute risk increase and number needed to screen. The numbers needed to screen were estimated using the absolute numbers computed by GRADEpro, which are calculated using control group event rate and relative risk with the 95% confidence interval (CI).
Results
Of the 7782 unique citations identified, 393 were screened in full and 2 studies, both RCTs, were included in our review ( Figure 1 ). The reference lists of 17 identified systematic reviews were searched; no citations were added to our database as a result. Characteristics of the included studies are provided in Table 2 .
Effectiveness of screening
Data on effect sizes reported by the studies are shown in Tables 3 and 4 , as are our GRADE ratings.
Referral outcomes
One RCT provided evidence on referral rates and time to referral for children less than 30 months of age who were screened for developmental delay using the Ages and Stages Questionnaire II (ASQ-II). 19 This 2013 group. Families allocated to intervention group A met with trained office staff to complete the screening tool with the use of props; families in intervention group B completed the ASQ-II without support of office staff or the use of props. Children were considered screen positive if they scored 2 SDs below the mean for age on any of the 5 developmental domains, and they could be referred to early intervention services. Children in the control group were considered screen positive if they failed the usual-care developmental screen (milestones of 8-10 questions from 4 domains), and they could also be referred to early intervention services.
There were significantly more referrals to early intervention in intervention group A than in the control group (RR 1.95, 95% CI 1.49-2.54) ( Tables 3 and 4 ). The absolute risk increase was 9.67%, and the number needed to screen for one child to be referred was 10 (95% CI [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . The referral rate was also significantly higher in intervention group B than in the control group (RR 1.71, 95% CI 1.30-2.25). The absolute risk increase was 7.24%, and the number needed to screen for one child to be referred was 14 (95% CI 8-33). Compared with the time to referral in the control group, the time was 70% shorter in intervention group A (rate ratio 0.30, 95% CI 0.19-0.48) and 64% shorter in intervention group B (rate ratio 0.36, 95% CI 0.23-0.59).
The GRADE ranking for time to referral and referral rates (for screening with or without office support) was moderate (Tables 3 and 4 ). Evidence from this study was downgraded for indirectness because participant age at enrolment was less than 12 months. 
Academic performance
The other RCT provided data on academic performance in children screened for language delay. 20 This 2007 study from the Netherlands included 11 440 boys and girls aged 15 months at enrolment (mean age not reported). Children randomly assigned to the intervention group were screened twice, at 18 and 24 months, with the VroegTijdige Onderkenning Ontwikkelingsstoornissen (VTO) Language Screening instrument; children assigned to the control group received usual monitoring. A final score ranging from 0 to 7 was assigned; children with a total score of 2 or less were referred for additional assessment to confirm language delay. After screening, the study did not offer an intervention and did not indicate whether children received interventions elsewhere.
Assessment of academic performance at age 8 years showed no differences between the study groups in any of the outcomes measured (attendance of a special school: RR 0.71, 95% CI 0.48-1.04; repeating a grade: RR 0.99, 95% CI 0.81-1.21; repeating a grade because of language problems in regular primary school: RR 1.26, 95% CI 0.89-1.80; being below the 10th percentile of oral tests: RR 0.88, 95% CI 0.63-1.23; being below the 10th percentile of reading tests in grade 2: RR 1.00, 95% CI 0.72-1.40; or being below the 10th percentile of spelling tests in grade 2: RR 0.68, 95% CI 0.41-1.13) (Tables 3 and 4) .
The GRADE ranking for all outcomes of academic performance was low (Tables 3 and 4 ). Evidence from this study was downgraded for potential risk of bias because of insufficient Records identified through database searches n = 7782
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Studies included in systematic review n = 2 Table 4 for footnotes. Note: ASQ-II = Ages and Stages Questionnaire II, CI = confidence interval, GRADE = Grading of Recommendations Assessment, Development and Evaluation, RR = relative risk, VTO = VroegTijdige Onderkenning Ontwikkelingsstoornissen Language Screening instrument. *The assumed risk in the control group is based on event rates in control groups across studies. The corresponding risk (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
a Using Cochrane's risk-of-bias tool, for this outcome the study was rated as having a low risk of bias. There was low risk of bias for all domains except blinding, which was assessed as being high risk because parents and clinicians were aware of their screening status. Because the control participants received usual care (developmental milestone screening) in this study, lack of blinding was not considered as having a large impact on outcomes of interest. Given that all of the information for this outcome is from a study with low risk of bias, the evidence was not downgraded for serious study limitations.
b
Because this was a single study, inconsistency could not be assessed. c This study included boys and girls < 12 months of age with an average risk of developmental delay (mean ages: intervention group A, 10.5 ± standard deviation 8.2 months; intervention group B, 10.5 ± 8.1 months; control group, 10.4 ± 8.6 months). The intervention groups were screened using ASQ-II (one group with office support [group A], one group without [group B]); the control group received usual care. The study took place in a primary care setting in the United States, and the report was published 2013. The evidence was downgraded because the population was not restricted to children aged 1-4 years. Adequate sample size (704 in intervention group A, 695 in control group) and sufficient number of events (140 in intervention group A, 71 in control group). The pooled effect estimate is precise, with a narrow 95% CI (RR 1.95, 95% CI 1.49-2.54). The evidence was not downgraded for imprecision. e There were too few studies (< 10) to assess publication bias. f Adequate sample size (693 in intervention group B, 695 in control group) and sufficient number of events (121 in intervention group B, 71 in control group). The pooled effect estimate is precise, with a narrow 95% CI (RR 1.71, 95% CI 1.30-2.25). The evidence was not downgraded for imprecision. Using Cochrane's risk-of-bias tool, for this outcome the study was rated as having unclear risk of bias. There was low risk of bias for all domains except allocation concealment and blinding of participants/personnel, which were assessed as having unclear risk of bias because there was insufficient information to evaluate these domains. Given that all of the information for this outcome is from a study with unclear risk of bias, the evidence was downgraded for serious study limitations. j This study included boys and girls aged 15 months at study entry with an average risk of developmental delay (mean ages not reported). The intervention group was screened using the VTO instrument; the control group received usual care. The study took place in a primary care setting in the Netherlands, and the report was published in 2007. There were no serious concerns regarding directness of this evidence. k Adequate sample size (3118 in intervention group, 2288 in control group), but fairly low number of events (83 in intervention group, 85 in control group). The pooled effect estimate is not precise, with a 95% CI that includes the no-effect value (RR 0.71, 95% CI 0.48-1.04). The evidence was downgraded for imprecision. Adequate sample size (3084 in intervention group, 2250 in control group) and sufficient number of events (443 in intervention group, 318 in control group). The pooled effect estimate is not precise, however, with a 95% CI that includes the no-effect value (RR 0.99, 95% CI 0.81-1.21). The evidence was downgraded for imprecision. Adequate sample size (2401 in intervention group, 1721 in control group) and sufficient number of events (146 in intervention group, 84 in control group). The pooled effect estimate is not precise, however, with a 95% CI that includes the no-effect value (RR 1.26, 95% CI 0.89-1.80). The evidence was downgraded for imprecision. n Adequate sample size (1270 in intervention group, 925 in control group) and sufficient number of events (112 in intervention group, 90 in control group). The pooled effect estimate is not precise, however, with a 95% CI that includes the no-effect value (RR 0.88, 95% CI 0.63-1.23). The evidence was downgraded for imprecision. o Adequate sample size (1844 in intervention group, 1328 in control group), but fairly low number of events (86 in intervention group, 62 in control group). The pooled effect estimate is not precise, with a 95% CI that includes the no-effect value (RR 1.00, 95% CI 0.72-1.40). The evidence was downgraded for imprecision. p Adequate sample size (1728 in intervention group, 1225 in control group), but low number of events (48 in intervention group, 52 in control group). The pooled effect estimate is not precise, with a 95% CI that includes the no-effect value (RR 0.68, 95% CI 0.41-1.13). The evidence was downgraded for imprecision.
information on allocation concealment and blinding of participants, and for imprecision because effect estimates included the null value.
Optimal interval and harms of screening
We found no studies meeting our inclusion criteria that reported on optimal intervals or harms of screening.
Interpretation
The evidence on the effectiveness of screening for developmental delay in improving cognitive, academic and adaptive functioning outcomes in children 1-4 years old is scant. We found one study that reported higher and earlier intervention rates among the children screened for developmental delay than among those in the control group. 19 Referral rate is an intermediate outcome; therefore, conclusions about long-term outcomes related to screening and referral to early intervention programs cannot be drawn from this study. The second study reported longer-term follow-up data (81 mo) on academic performance outcomes among children screened at 18 and 24 months for speech and language delay. In this study, screening did not show a significant improvement in academic outcomes at age 8 years. Ideally, the intermediate outcome of early referral leads to early interventions, which then improve longterm outcomes. Unfortunately, our evidence does not confirm this. Furthermore, we found no evidence on which screening intervals are most effective and which result in the least harm.
We did not investigate treatment of developmental delay. As such, we have no evidence on the effectiveness of early intervention programs: the first study investigated only to the point of referral, and the second one did not indicate whether the children received an early intervention program between the initial screen and the 8-year assessment. The evidence on the effectiveness of screening is limited and inconclusive; as such, we cannot comment on the effectiveness of early intervention programs and their impact on cognitive, academic and adaptive functioning.
Currently, no guidelines exist on screening for global developmental delay. The findings of this systematic review are in keeping with the most recent guideline (2015) from the US Preventive Services Task Force, which found insufficient evidence on screening for speech and language delay in children up to 5 years. 8 Despite the lack of evidence found in this review and in the US Preventive Services Task Force's systematic review on screening for speech and language in children less than 5 years old, 21 screening of children is regularly implemented and endorsed. In the US, the American Academy of Pediatrics recommends screening for developmental delay at regular intervals up to 30 months. 9 In Canada, Ontario uses the NDDS as a surveillance tool to monitor for developmental delay in children at the 18-month well-baby visit. Despite common use, we found no peer-reviewed RCT evidence on the NDDS tool. A recent Canadian observational study evaluated the NDDS and found evidence that the tool should not be used on its own (unpublished data). Further investigation into these commonly used tools is required to determine whether their continued use is clinically relevant and appropriate.
Limitations
The inclusion and exclusion criteria for this review limited our results. First, only publications in English or French were considered for inclusion. Second, for the question of effectiveness of screening, only RCTs and controlled cohort studies were included, thus excluding observational studies that may have reported on our outcomes of interest. Although this limited the breadth of evidence available, it ensured a higher quality of evidence. Third, because we selected high-level, long-term outcomes (e.g., cognitive, academic and adaptive functioning), studies reporting on shorter-term, specific outcomes (e.g., changes in expressive or receptive language or changes in social or motor functioning) and on outcomes related to symptoms of autism spectrum disorders were excluded. Based on our exclusion criteria, it is clear that there is research focused on these immediate outcomes, rather than on the long-term outcomes our review aimed to report on. Publication bias and methodologic inconsistency could not be assessed due to the paucity of studies.
Conclusion
The evidence on screening for developmental delay in asymptomatic children aged 1-4 years to improve cognitive, educational and adaptive functioning outcomes is inconclusive. Further research on effectiveness and harms, with longer-term outcomes, is needed to inform decisions about screening and screening intervals.
